Ralfinamide

Summary

Ralfinamide (CHEMBL2107771) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including neuralgia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 2
• Chemistry: 302.34 Da · C17H19FN2O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2107771
Name	Ralfinamide
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	5745207
Molecular formula	C17H19FN2O2
Molecular weight	302.34
InChIKey	BHJIBOFHEFDSAU-LBPRGKRZSA-N

SMILES: C[C@@H](C(=O)N)NCC1=CC=C(C=C1)OCC2=CC=CC=C2F

IUPAC name: (2S)-2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]propanamide

Also known as: FCE-26742A, Nw-1029, NW1029, PNU-0154339E, Priralfinamida, Priralfinamide, Ralfinamide, RALFINAMIDE, PRIRALFINAMIDE, priralfinamide

Patent coverage: 95 distinct patent families (340 SureChEMBL compound mentions), from 2 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Amine oxidase [flavin-containing] B, Sodium channel protein type 9 subunit alpha.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P19643	6.7	IC50	200	nM	CHEMBL_ACT_17685261

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neuralgia	2	MONDO:0021667	EFO:0005762

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01019824	PHASE3	COMPLETED	Efficacy and Safety of Ralfinamide in Patients With Chronic Neuropathic Low Back Pain
NCT00736151	PHASE2	COMPLETED	Phase II Dose Titration Study in Patients With Neuropathic Pain

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).